These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17767433)

  • 1. Health technology assessment in England: assessment and appraisal.
    Walley T
    Med J Aust; 2007 Sep; 187(5):283-5. PubMed ID: 17767433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health technology assessment in England and Wales.
    Stevens A; Milne R
    Int J Technol Assess Health Care; 2004; 20(1):11-24. PubMed ID: 15176173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health technology assessment for the NHS in England and Wales.
    Woods K
    Int J Technol Assess Health Care; 2002; 18(2):161-5. PubMed ID: 12053415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
    Littlejohns P; Barnett D; Longson C;
    Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries.
    Corbacho B; Drummond M; Santos R; Jones E; Borràs JM; Mestre-Ferrandiz J; Espín J; Henry N; Prat A
    Eur J Health Econ; 2020 Jun; 21(4):621-634. PubMed ID: 32026155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
    Birch S; Gafni A
    Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
    [No Abstract]   [Full Text] [Related]  

  • 10. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
    Davies E; Littlejohns P
    J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Spanish Network of Agencies for Health Technology Assessment and Services of the National Health System (RedETS).
    Serrano-Aguilar P; Asua-Batarrita J; Molina-López MT; Espallargues M; Pons-Rafols J; García-Armesto S; Arriola-Bolado P; López-García M; Faraldo-Vallés MJ; Sánchez-Gómez LM; Juárez-Rojo C; Prieto-Yerro I; Casado-Durández P; Sarria-Santamera A
    Int J Technol Assess Health Care; 2019 Jan; 35(3):176-180. PubMed ID: 31006412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradigms in operation: explaining pharmaceutical benefit assessment outcomes in England and Germany.
    Kieslich K
    Health Econ Policy Law; 2020 Jul; 15(3):370-385. PubMed ID: 30975237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of health technology assessment in shaping the benefits package in The Netherlands.
    Stolk EA; de Bont A; van Halteren AR; Bijlmer RJ; Poley MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):85-94. PubMed ID: 19371181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health technology assessment in Europe. Improving clarity and performance.
    Cookson R; Maynard A
    Int J Technol Assess Health Care; 2000; 16(2):639-50. PubMed ID: 10932428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment and evidence-based policy making: Queensland Department of Health experience.
    Ju H; Hewson K
    Int J Technol Assess Health Care; 2014 Dec; 30(6):595-600. PubMed ID: 25816825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.
    Denburg AE; Giacomini M; Ungar WJ; Abelson J
    Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.